This week, we will discuss the a small step forward in understanding the role of anticoagulation in atrial fibrillation in ESRD.
The AskASN Chat: Follow up FAQs
SODIUM-HF in Kidney Medicine
The NephJC editorial in Kidney Medicine is live. Great work from Sheikh Khalid, Rachel Hung, and William Vasquez Espinosa, supported by Nayan, Joel, and Jamie.
Read it here.
Ask ASN: A special NephJC
Water, Water Everywhere: The Diuretic Wars Continue!
What’s your loop and thiazide of choice? Do you know which diuretics are better, faster, stronger? This week’s TenTweets is a two-fer (Chlorthalidone vs HCTZ and Furosemide vs Torsemide). Tweetorial catch-up here.
TRANSFORM-HF: Solving the Diuretic Mystery with a Twist of Vintage vs Modern
The Distal Convoluted Tubule Showdown: Chlorthalidone versus HCTZ
The TRANSFORM-HF Visual Abstract
Does Torsemide lower all cause mortality compared to furosemide for heart failure patients post-hospitalization? Cristina Popa elaborates, visually!
The Diuretic Comparison Project Visual Abstract
Is Chlorthalidone superior to Hydrochlorothiazide in preventing major adverse cardiovascular events? Here is the VA from Mike Turk
The good news is there was a huge trial in Alport syndrome published
The bad news is it was on bardoxolone. Tweetorial catch-up here.
Freely Filtered does STOP ACE
Episode 055: The Filtrate try to figure out STOP ACE with the assistance of Laurie Tomlinson.
The CARDINAL Visual Abstract
Does Bardoxolone help patients with Alport’s Syndrome? Dr M Abdul Qader explains graphically.
CARDINAL Sin: Bardoxolone and Alport Syndrome
IgA and steroids: the saga continues
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
NefIgArdians of The Glomerular Galaxy
NefIgArd trial : Visual Abstract
Check out the Delightful Visual Abstract for the NefIgArd trial by Priti Meena
The Top Nephrology Stories of 2022
Introducing "NephJC Collections"
Checking in on MyTEMP - #TenTweetNephJC
The last NephJC of the year brought us a cool discussion on if cooling dialysate could help mitigate the effects of intradialytic hypotension. Get caught up with the chat in the latest edition of #TenTweetNephJC.
Freely Filtered does minimal change disease and anti-nephrin antibodies
Episode 042: Minimal change disease has classically been described as having negative immunofluorescence and to not be antibody mediated. But here comes Dr Weans with a fresh study smashing this orthodoxy. She proposes anti-nephrin antibodies as the etiologic agent driving minimal change disease.